Pharma News

DelMar Pharmaceuticals complete End-of-Phase 2 Meeting with FDA on VAL-083

  • Posted on: 26 May 2016
  • By: Shalini.Sharma

DelMar Pharmaceutical Inc. announced the successful completion of an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA).


FDA Accept Allergan’s NDA Filing for Oxymetazoline HCI Cream 1.0%

  • Posted on: 26 May 2016
  • By: Shalini.Sharma

Allergan plc. announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults, has been accepted by the U.S. Food and Drug Administration (FDA) for standard review. Allergan expects the Prescription Drug User Fee Act (PDUFA) date to be in the first half of 2017.


Zambon Launch Xadago in UK

  • Posted on: 26 May 2016
  • By: Shalini.Sharma

Zambon S.p.A., an international pharmaceutical company committed to the CNS therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (Newron), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the CNS and pain, announced the availability of Xadago (safinamide) in the United Kingdom.


Dr. Reddy ’ s enters the branded consumer health arena through the acquisition of six OTC brands

  • Posted on: 26 May 2016
  • By: Gayatri Mahajan

Hyderabad, India and Princeton, NJ, USA Dr.Reddy’s Laboratories Ltd.(BSE: 500124, NSE:DRREDDY, NYSE: RDY) today announced the acquisition of an  eminent portfolio of over the counter (OTC) brands in the cough and cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN’S®, BUFFERIN®, NUPERCAINAL® Ointment, CRUEX ® Nail  Gel, COMTREX ® , and MYOFLEX ®.


New study surveys genetic changes linked with Parkinson's disease

  • Posted on: 25 May 2016
  • By: Gayatri Mahajan

After Alzheimer's, Parkinson's disease (PD) is the leading neurodegenerative disorder, affecting close to a million Americans, with 50,000 new cases diagnosed every year. A progressive disorder of the nervous system affecting movement, PD typically strikes adults in mid-life. In many cases, the spread of the disease to other brain areas leads to Parkinson's disease dementia, characterized by deterioration of memory, reason, attention and planning.


Chemo, radiation, surgery combo boosts survival for pancreatic cancer patients

  • Posted on: 25 May 2016
  • By: Gayatri Mahajan

In roughly one-third of pancreatic cancer patients, tumors have grown around the pancreas to encompass critical blood vessels. Conventional wisdom has long held that surgery to remove the tumors is rarely an option, and life expectancies are usually measured in months. Mayo Clinic, teaming oncologists, gastrointestinal and vascular surgeons and others, is finding that many of these patients actually are candidates for surgery. Mayo has been fine-tuning a protocol to treat them, and in two studies, found survival now stretching into years.


Pages